Pasadena Private Wealth’s Clovis Oncology, Inc. CLVS Stock Holding History

Pasadena Private Wealth’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-25,000	Closed	-$30K	–	125
2022 Q3	$30K	Hold	25,000	–	–	0.01%	87
2022 Q2	$45K	Hold	25,000	–	–	0.02%	86
2022 Q1	$51K	Hold	25,000	–	–	0.02%	94
2021 Q4	$68K	Buy	+25,000	New	+$92.4K	0.02%	105

Other funds holding CLVS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

CAS

Coppell Advisory Solutions Coppell, Texas $1.21B AUM 20.39% 1-Year Est. Return

CASC

Coppell Advisory Solutions Corp Coppell, Texas $531M AUM

STB

S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

FFWM

Future Financial Wealth Management Cincinnati, Ohio $160M AUM 21.24% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $808M AUM 51.1% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Pasadena Private Wealth's CLVS Position: Q4 2022 in Review

Pasadena Private Wealth sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 25,000 shares — an estimated $30K sold.

Pasadena Private Wealth first reported a position in CLVS in Q4 2021 and held it in 4 quarters. The position peaked at $68K in Q4 2021. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

Pasadena Private Wealth reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
Pasadena Private Wealth sold 25,000 Clovis Oncology, Inc. shares in Q4 2022, an estimated $30K.
Pasadena Private Wealth first reported a position in Clovis Oncology, Inc. in Q4 2021 and held it in 4 quarters.
Pasadena Private Wealth's Clovis Oncology, Inc. position peaked at $68K in Q4 2021.
15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Pasadena Private Wealth's 13F filing for Q4 2022, filed 2 Feb 2023.